The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres.

Teodora Spataru, Remus Popescu, Monica State, Mihai Pahomeanu, Bogdan Mateescu, Lucian Negreanu

Abstract read

In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease.World journal of gastroenterology · 2025
Observational

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Teodora SpataruGastroenterology 1 Department, University Hospital, Carol Davila University, 020021 București, Romania.

Remus PopescuGastroenterology 1 Department, University Hospital, Carol Davila University, 020021 București, Romania.

Monica StateGastroenterology Department, Colentina Hospital, Carol Davila University, 020021 București, Romania.ORCID 0000-0003-4961-3476

Mihai PahomeanuGastroenterology 1 Department, University Hospital, Carol Davila University, 020021 București, Romania.ORCID 0000-0002-7052-4294

Bogdan MateescuGastroenterology Department, Colentina Hospital, Carol Davila University, 020021 București, Romania.ORCID 0000-0002-2607-8653

Lucian NegreanuGastroenterology 1 Department, University Hospital, Carol Davila University, 020021 București, Romania.ORCID 0000-0003-3042-0754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the last two decades, an increased number of molecules with multiple mechanisms of action have been approved for the treatment of inflammatory bowel disease (IBD), with a substantial increase in the costs related to therapy, which has become a concern for payers, regulators, and healthcare professionals. Biosimilars are biologic medical products that are highly structurally similar to their reference products; have no clinically meaningful differences in terms of immunogenicity, safety, or effectiveness; and are available at a lower price.

Indexed as

Adalimumabbiosimilarsinflammatory bowel diseasenon-medicalswitch

Identifiers

PMID39458960

DOI10.3390/ph17101319

PMCPMC11510052

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.